Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Management Appointments

26 Jul 2006 07:01

Torex Retail PLC26 July 2006 Torex Retail Plc ("the Company") Announces non-Board appointments for Operational Management to deliver Organic Growth Strategy & Further strengthening of Finance Function Torex Retail Plc, an international market leader in the provision of innovativeretail IT systems, announces that following the completion of its 2006acquisition strategy, the Company's operational management is to be restructuredinto five newly created Divisions in order to fully focus on maximising organicgrowth opportunities in the coming period. As a result, the following senior internal appointments have been made,reporting directly to the Plc Board: • CEO of UK General Retail: Doug Hargrove (age 39) (Previously Chief Operating Officer, UK & Ireland) • CEO of Overseas Business: Phil Cox (age 39) (Previously Group Treasury Officer) • CEO of Hospitality & QSR ('Quick Service Restaurants'): Keith Pascal (age 41) (Previously VP Sales & Marketing, Savista Inc.) • CEO of P&C ('Petroleum & Convenience'): Brendan Kavanagh (age 41) (Previously Head of P&C Division Worldwide) • CEO of Americas General Retail: Mike Hess (age 43) (Previously President & COO of Torex North America) The Company is also pleased to today announce the appointment of Marcus Leek asGroup Finance Director with immediate effect. Marcus (age 31) joins from 4uBusiness Ltd (a part of the Caudwell Group) where he held the position ofFinance Director. He also has considerable experience in the retail sectorhaving worked for J. Sainsbury plc and Bells Stores Limited in a variety ofsenior finance roles. Marcus is an industry trained Chartered Accountant. Reporting directly to Mark Pearman, Marcus will be responsible for all groupfinancial matters. Marcus will be part of the wider senior management team atTorex as well as playing a leading role in the finance function. He will alsoplay an active part in investor relations. Continuing Plc Finance Director and Business Development Director Mark Pearmancommented: "I am delighted that we have secured the services of Marcus. He is highlyqualified and his relevant industry experience and energy make him the choicecandidate; we expect him to make an immediate contribution to the Group". Supporting Marcus will be Mark Lovett (age 32) as UK Finance Director. Markjoins Torex Retail from Xansa plc, an IT and Business Process Outsourcingprovider, where for the past 12 months he was Finance Director for the Financialand Business services division. Prior to that, Mark was Financial Controller forthe Retail division, where he worked on new and existing contracts withretailers such as Boots, Tesco, B&Q and Marks & Spencer. Having trained as aChartered Accountant with KPMG, Mark subsequently held a number of financepositions with Misys plc in the UK, North America and Far East. On the new management appointments, Chairman and Chief Executive Chris Moorestated: "Following the completion of our recent acquisition strategy, we have nowachieved the sufficient scale necessary to compete globally. It was clear thatas we entered our next phase of organic-focused growth, we needed an experiencedmanagement team and structure that could successfully drive this strategythroughout the Group. The five new CEO appointments reflect this and will alsomake for a clearer reporting structure at Board level. It was also important for us to strengthen our internal finance function toreflect the new size of the Company. I am delighted to have secured thehigh-calibre services of Marcus Leek and Mark Lovett who join us with clearfinancial and industry focus in Retail and IT". Torex Retail Plc will announce interim results for the six months ended 30 June2006 on Monday, 14 August. As stated in the recent 11 July trading update,management expect these results to be slightly ahead of analyst's expectationsand remain confident for the full year. -Ends- Enquiries: Torex Retail PlcChris Moore, Chairman & Chief Executive +44 (0)870 300 6061 Citigate Dewe Rogerson +44 (0)20 7638 9571Seb Hoyle / Lucie Holloway This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jan 20267:00 amRNSSecondary Trading Following Cancellation
7th Jan 20267:00 amRNSCancellation - Tissue Regenix Group Plc
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
17th Dec 20256:00 pmRNSTissue Regenix Group
8th Dec 20257:00 amRNSUpdate re. proposed cancellation of shares
4th Dec 20252:40 pmRNSProposed £17.5m CLN raise, cancellation of Trading
1st Dec 20257:00 amRNSFurther re. financial update and funding plans
7th Nov 20257:00 amRNSFinancial update and funding plans
22nd Oct 20253:29 pmRNSStatement re. Suspension
22nd Oct 20252:02 pmRNSSuspension - Tissue Regenix Group PLC
17th Oct 20257:00 amRNSCFO joins Board
16th Oct 20257:00 amRNSUpdate re. FY24 & H125 restatement & Board Changes
9th Oct 20257:00 amRNSHolding(s) in Company
6th Oct 20253:29 pmRNSHolding(s) in Company
3rd Oct 20253:01 pmRNSHolding(s) in Company
2nd Oct 20254:43 pmRNSHolding(s) in Company
1st Oct 20255:35 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
17th Sep 20257:00 amRNSNotice of Results
8th Sep 20257:01 amRNSHalf-Year Trading Update and Notice of Results
8th Sep 20257:00 amRNSBoard Changes
1st Aug 20257:00 amRNSDirectorate Change
23rd Jul 20251:52 pmRNSResult of AGM
4th Jul 20257:00 amRNSGrant of share options
27th Jun 20257:00 amRNSPosting of Annual Report & Notice of AGM
25th Jun 20257:00 amRNSFinal results for the year ended 31 December 2024
9th Jun 20257:00 amRNSCE & UKCA certification for OrthoPure® XT
24th Apr 20259:38 amRNSForm 8.5 (EPT/NON-RI)- Tissue Regenix Group Plc
15th Apr 20259:23 amRNSForm 8.5 (EPT/NON-RI)
10th Apr 20259:09 amRNSForm 8.5 (EPT/NON-RI)
9th Apr 202510:45 amRNSForm 8.5 (EPT/NON-RI)
8th Apr 20257:00 amRNSConclusion of Strategic Review & Offer Period
7th Apr 20258:46 amRNSForm 8.5 (EPT/NON-RI)
1st Apr 20259:12 amRNSForm 8.5 (EPT/NON-RI)
31st Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
27th Mar 20257:00 amRNSEuropean patent granted
25th Mar 20258:58 amRNSForm 8.5- Tissue Regenix Group Plc
21st Mar 20258:36 amRNSForm 8.5 (EPT/NON-RI)
20th Mar 20259:19 amRNSForm 8.5 (EPT/NON-RI)
19th Mar 20258:55 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20257:00 amRNSCompany update
12th Mar 20259:27 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 20259:30 amRNSForm 8.5 (EPT/NON-RI)
6th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
5th Mar 20258:54 amRNSForm 8.5 (EPT/NON-RI)
4th Mar 20259:28 amRNSForm 8.5 (EPT/NON-RI)
3rd Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 20258:56 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.